Hoffmann, M., Chavez, J., Westin, J., Jørgensen, J., Muñoz, J., Carpio, C., Perini, G., Bachy, E., Campbell, V., Riley, C. H., Morschhauser, F., Morillo, D., Akyol, A., Moucheron, B. D., Pourdehnad, M., Sudhindra, A., Carrancio, S., Voetsch, J., Yang, G., Perna, S., Michot, J. (2025). Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Phase 1/2 study extended follow-up Results. Blood. https://doi.org/10.1182/blood-2025-479